IMPORTANCE Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differences not only in cancer biology but also in the thoroughness of the nodal examination.
T he TNM staging system remains the most prognostically discriminative method in lung cancer. 1 The system communicates the extent of disease, suggests treatment options, provides a means of homogenizing groups of patients enrolled into clinical trials, and enables objective outcome comparisons. Improving the prognostic value of the TNM staging system is of interest by identifying independent but complementary prognostic factors, including genetic profiles of early-stage cancer that can identify patients with higher mortality risk within specific stage subsets.
2 Such progressive work is impaired by variation in the quality of application of the TNM staging criteria.
3,4
Nodal staging is the most variable and potentially inaccurate of the TNM criteria. Variation in the thoroughness and accuracy of clinical and pathologic nodal staging is well reported.
5-10 Pathologic nodal staging is more accurate than clinical staging. 11 However, current pathologic staging quality ranges from nonexamination of lymph nodes (the pNX phenomenon) 9 and poor examination of hilar or intrapulmonary (N1) 12 and mediastinal lymph nodes to guidelineconcordant staging. 8, 13 However, even guideline-concordant nodal staging varies in the specific requirements, depending on the guideline. [13] [14] [15] [16] The International Association for the
Study of Lung Cancer (IASLC) Staging and Prognostic Factors
Committee recently reported major intercontinental variation in pN category-stratified survival, with significantly higher survival among Asian patients with pN0 and pN1 findings than among patients from America, Australia, and Europe.
17
Whether these differences reflect biological differences in the intercontinental populations with lung cancer or whether they reflect differences in surgical and pathologic practices in nodal staging remains unclear. 18 We examined long-term postoperative survival in a US regional population with detailed information on the thoroughness of nodal staging to examine the stage-stratified survival effect of sequentially more thorough nodal examination based on existing examination criteria with and without modifications.
Methods
The Mid-South Quality of Surgical Resection (MS-QSR) cohort is a population-based database of lung cancer resections with curative intent that currently includes more than 90% of cases at all hospitals with at least 5 annual cases in 4 contiguous US Dartmouth hospital referral regions in northern Mississippi, eastern Arkansas, and western Tennessee from 2009 onward. 19 These states have the second, third, and fourth highest rates of lung cancer incidence and mortality, respectively, in the United States. 20 The current analysis of resections from January 1, 2009, through January 25, 2016, excludes patients who received neoadjuvant therapy (to avoid confounding from treatment effects on nodal counts), who died within 30 days of surgery (because of our interest in examining quality association of pathologic nodal staging with long-term outcomes), or who had small cell lung cancer and carcinoid tumors (because of their different long-term survival patterns). Survival status in the MS-QSR cohort is actively obtained from institutional clinical records or provided by each institution's tumor registry and systematically updated for all patients every 12 months. The institutional review boards at each participating institution approved this research with a waiver of the requirement for informed consent.
Quality-Based Cohort Selection Strategy
We evaluated the N category-stratified survival in analytic cohorts selected with sequentially greater quality stringency. ; and those with R0 and examination of at least 1 N1 lymph node, a minimum of 10 nodes, and a minimum of 3 mediastinal nodal stations (a combination of the NCCN and CoC criteria) (group 8) ( Figure 1 and Table 1 ).
Statistical Analysis
Univariate frequency (percentages) or means (SDs) are reported for each variable of interest. Overall and pN categorystratified survival estimates were calculated using the KaplanMeier method and evaluated graphically. Survival time was defined as years from the date of surgery to the date of death or last follow-up (censored patients). One-, 3-, and 5-year survival estimates were reported, and survival curves were compared between groups with the log-rank test. We used Cox pro-portional hazards models to estimate crude and adjusted hazard ratios (HRs) with 95% CIs comparing pN categories. Statistical comparisons are made between pN categories within each quality cohort, including all patients meeting the quality criteria ( Figure 1 ). All statistical comparisons of overall survival between quality cohorts compare independent groups of patients, such that each patient is only counted once, as part of the highest-quality cohort attained. P < .05 was considered to be statistically significant, and all analyses were conducted using SAS software (version 9.4; SAS Institute).
Results

Cohort Characteristics
The The distribution of histologic type, grade, or tumor size did not change substantially when more stringent quality restrictions were applied (eTables 1 and 2 in the Supplement). Pathologic T and N categories also appeared to be consistent across quality categories except for the exclusion of pNX in groups 3 through 8, which required the examination of at least 1 lymph node (eTables 1 and 2 in the Supplement). Overall, 153 patients (7.5%) had positive margins; 145 patients (7.1%), pNX findings. Adjuvant chemotherapy was used in 337 patients (16.5%); radiation therapy, in 95 (4.6%).
Oncologic Resection Quality Subcohorts
The proportion of patients in each analytic subcohort was inversely proportional to the degree of stringency of the quality criteria. Numbers of patients ranged from 1894 (92.5%) for group 2 (R0 resection) to 541 (26.4%) for group 8 using the combination of the NCCN and CoC criteria ( Figure 1 ).
Association With Aggregate Overall Survival
Aggregate overall survival and survival stratified by pN category were evaluated within each sequentially more stringent quality cohort. Aggregate 3-year survival estimates increased from 69% (95% CI, 67%-72%) for group 1 to 75% (95% CI, 70%-79%) for group 8; aggregate 5-year survival estimates showed an absolute increase of 8% from group 1 (57%; 95% CI, 54%-60%) to group 8 (65%; 95% CI, 58%-72%) (eTable 3 and eFigure, A, in the Supplement). After adjusting for age at surgery, sex, race, insurance status, histologic type, extent of surgical resection, number of comorbidities, pN category, and pT category, patients with resections meeting the most stringent quality definition (group 8 [n = 541]) had a 24% reduction in the hazard of death (adjusted HR, 0.76; 95% CI, 0.62-0.95; P = .01) compared with patients with R0 and less stringently defined nodal staging quality (groups 2-7 [n = 1353]) and a 40% reduction in death compared with resections meeting the least-stringent quality definition (non-R0 group 1 [n = 153]) (adjusted HR, 0.60; 95% CI, 0.43-0.83; P = .002). We found a sequential 2% improvement in aggregate survival with each level of stringency from groups 1 to 4 (5-year survival, 0.57, 0.59, 0.61, and 0.63, respectively) and from groups 5 to 6 (5-year survival, 0.63 and 0.65, respectively); aggregate survival was similar between groups 4 and 5 and between groups 6 and 8 (5-year survival, 0.65 for both) (eFigure, A, in the Supplement).
Association With Comparative N Category-Stratified Survival
The delineation in 5-year survival curves between patients with pN1 (0.46; 95% CI, 0.38-0.54) and pN2 (0.41; 95% CI, 0.32- Group criteria are described in detail in Table 1 . (Figure 2 and Figure 3) . Although the aggregate survival among patients meeting the CoC criteria (group 4) was similar to that among patients meeting the UICC criteria (group 5), we found a complete separation of the pN1 and pN2 survival curves with the greater thoroughness of mediastinal nodal examination mandated by the UICC criteria ( Figure 3A )compared with the CoC criteria ( Figure 2D ), which did not specify from where the mandated minimum of 10 examined lymph nodes should be derived and in which overlap occurred in the pN1 and pN2 survival curves. Similarly, groups 7 and 8, for whom a minimum of 3 examined mediastinal nodal stations were required, showed clear separation of the pN0, pN1, and pN2 survival curves ( Figure 3C and D). The requirement for examination of at least 1 mediastinal lymph node among the minimum of 10 nodes mandated by the CoC (group 6) did not resolve the lack of precision between pN1 and pN2 prognostication ( Figure 3B ). Only 40 patients who had 10 or more examined lymph nodes failed to meet the requirement for at least 1 mediastinal lymph node (eTables 1 and 2 in the Supplement).
Discussion
The TNM staging method serves to compare patients across time and space, provides a means of estimating risk for death, enables the identification of candidates for adjuvant therapy, and provides a means of homogenizing comparison groups in clinical trials.
2,22 Nodal staging is the most difficult component of the TNM constructs to accurately determine because of variability in use and accuracy of clinical staging tests 5, 6, 23 and in the thoroughness of application of pN staging procedures.
3,4,7
The IASLC Staging and Prognostic Factors Committee 17 recently demonstrated significant differences in survival among patients with pN0, pN1, and pN2 NSCLC in the international database used to reconfigure the TNM staging descriptors. Fiveyear survival among Asian patients (mostly from Japan and South Korea) with pN0, pN1, and pN2 disease was 79%, 54%, and 39%, respectively, compared with 67%, 48%, and 42%, respectively, among American patients (mostly from 2 major US institutions); 58%, 41%, and 33%, respectively, among Australian patients; and 54%, 34%, and 22%, respectively, among European patients. 17 Two plausible explanatory hypotheses for these differences are intercontinental differences in cancer biology and differences in the thoroughness of lymph node examination.
18
We tested the latter hypothesis by examining stagestratified survival in cohorts of patients with sequentially more thorough lymph node examination. We observed that sequential quality curbs were strongly associated with improved outcomes. Moreover, the association between the specific quality criteria and the pattern of survival improvement suggests Mandating examination of a minimum of 10 lymph nodes (as the CoC has done) was associated with the biggest increase in pN0 survival, suggesting the value of more thorough retrieval of N1 nodes.
12,27,28 Imposition of a specific requirement for mediastinal nodal examination, especially the NCCN recommendation to examine a minimum of 3 mediastinal nodal stations, was associated with the biggest increase in N1 survival, suggesting more accurate detection of N2 nodal metastasis. 21 Only the cohorts that mandated examination of multiple mediastinal lymph nodes (group 5 [ Figure 3A ]) or multiple mediastinal lymph node stations (groups 7 and 8 [ Figure 3C and D]) achieved separation in survival between patients with pN1 and pN2 disease. Therefore, the highestquality recommendations should mandate examining a minimum of 10 total lymph nodes, with sampling from at least 3 mediastinal stations. The quality of pN staging matters. All the virtues of the TNM staging system inhere in its risk-stratification value, which relies heavily on proper application. Loss of this prognostic ability was demonstrated in the evolving stage-stratified sur- Group criteria are described in detail in Table 1 . In group 1, pNX, pN1, and pN2 survival curves converged. In group 2, the survival pattern is indistinct from that of group 1. In group 3, the pNX group was eliminated, but pN1 and pN2 survival curves converged. In group 4, residual overlap remained between pN1 and pN2 survival curves. + Indicates censored patients.
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vival plots, in which increased stringency of N1 and mediastinal nodal examination eliminated overlaps between stagestratified survival plots and improved the separation between the pN strata (Figures 2 and 3 ). This finding suggests that the full prognostic value of the TNM system depends on the thoroughness of application and that imposition of survivalimpactful quality criteria is required in analysis cohorts used to test the prognostic value of nodal staging descriptors. Of particular concern is the potential effect of heterogeneity in thoroughness of nodal examination on the design, accrual, results, and interpretation of clinical trials.
Limitations
We excluded patients who died within 30 days of surgery because we were interested in examining the long-term survival impact of oncologic quality of resection and needed to eliminate potential confounding caused by short-term postoperative mortality. The causes of postoperative mortality have been figured out and are more or less universally agreed on.
29
In addition, this nonrandomized observational study was subject to the limitations, including biases and potential confounding inherent in such a study design. Furthermore, we did not examine the influences of institutional and clinician factors. The institutions in this study are involved in ongoing surgical quality improvement initiatives, which may affect the surgical sampling of lymph nodes and the quality of pathologic examination.
We also did not test the alternative, biological hypothesis of the intercontinental outcome differences in stagestratified lung cancer survival nor did we prove the quality of pN category pN0 pN1 pN2
Group criteria are described in detail in Table 1 . In group 5, separation occurred among pN0, pN1, and pN2 survival curves with the greater stringency of mediastinal lymph node examination requirement based on the number of mediastinal nodes. In group 6, lack of mediastinal nodal mapping stringency failed to separate pN1 and pN2 survival curves. In group 7, separation occurred among the pN0, pN1, and pN2 survival plots, but the pN1 survival was closer to the pN0 curve. In group 8, combination of the American College of Surgeons Commission on Cancer and National Comprehensive Cancer Network criteria shows the most balanced separation between the survival plots, by coupling thorough hilar and intrapulmonary lymph node examination with thorough mediastinal lymph node examination based on station mapping. + Indicates censored patients. staging hypothesis because we could not directly compare the IASLC and MS-QSR cohorts. Nevertheless, we used this unique population-based database, which has significantly more details about nodal staging than are available in other large databases, such as the Surveillance, Epidemiology and End Results database or the National Cancer Data Base, to examine a problem in lung cancer care, namely, the disparity in outcomes between individuals with ostensibly identical stage of disease. We could not determine from this analysis whether the survival differences resulted from stage migration with more thorough nodal examination or whether there is an inherent survival benefit from more thorough examination (as potentially suggested by differences in aggregate or non-stagestratified survival differences). Finally, any quality metric that uses the number of examined lymph nodes is subject to potential confounding from the manner of counting lymph node fragments.
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Conclusions
Future examinations of the nodal staging criteria should highlight the need to standardize staging quality with use of highquality analytic cohorts at least in sensitivity analyses. The IA-SLC has started in this direction with examination of the effect of excluding incomplete resections from the final analysis cohort. We recommend further evaluation by incorporating sensitivity analyses of sequentially more stringent nodal quality subsets in analyses leading to future updates of the TNM staging system. Meanwhile, efforts to disseminate improved surgical and pathologic nodal staging practices must be actively promoted. Progress in understanding the elemental question of heterogeneous cancer biology and the development of stageindependent prognostic factors are potentially submerged within the quality gap of nodal staging. report a worldwide simulation of nodal staging using a regional database and highlight 2 important facts. First, lung cancer physicians are using different rules for nodal staging, and second, this difference matters. This article demonstrates that, as increasingly stringent nodal examination criteria are applied based on the current existing various guidelines, the prognosis of different nodal stages diverge further, proving that the quality of lymph node assessment has a direct influence on prognosis. Whether this influence is attributable to stage migration or more thorough surgical resection has yet to be determined. Considering that within this regional database, the number of surgical resections that attained any compliance with the currently existing 3 guidelines was 40% and that 26% of patients failed to have a single mediastinal lymph node included in the pathology report, 1 problem was well demonstrated. The exact reasons for such variability in the quality of mediastinal nodal dissection in North America are unclear. We believe that the problem is largely 2-fold: lack of a universally accepted guideline for mediastinal nodal dissection and lack of implementation of the current guidelines perhaps owing to poor awareness, surgeon comfort level, and pathologist expertise.
Mandating a minimum of 10 lymph nodes was associated with increased pN0 survival. Obtaining 10 lymph nodes for pathologic examination can be a function of nodal retrieval by the surgeon, but given the prevalence of lymph nodes within and around lung tissue, thoroughness of pathologic examination likely plays a significant role. Within tightly controlled surgical lymphadenectomy specimens, the number of lymph nodes examined continued to be associated with accuracy of nodal staging and survival, 4 suggesting that pathologist practice is a significant contributor to the thoroughness of the pN staging. The second clue is the increase in N1 survival seen with mandated examination of mediastinal nodes. Mediastinal lymph node dissection is a necessary and critical portion of the resection of early-stage lung cancer, and the weight of responsibility is directed toward surgeons. These clues point toward the need for multidisciplinary efforts to improve and maintain the quality of pN staging. A multidisciplinary tumor board involving pathologists, surgeons, and medical oncologists is one method of rapidly spreading, confirming, and upholding standards within an institution. Finally, a completely different but related question is, in the era of stereotactic body radiation therapy (SBRT) for early lung cancers and increasing incidence of patients undergoing SBRT without surgical staging of the mediastinum, what do these data imply for that trend and the prognosis of patients undergoing such therapy? The need for invasive mediastinal nodal staging, in addition to positron emission tomography and computed tomography, has been demonstrated in studies 
